1. Home
  2. RCEL vs BGX Comparison

RCEL vs BGX Comparison

Compare RCEL & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCEL
  • BGX
  • Stock Information
  • Founded
  • RCEL N/A
  • BGX 2010
  • Country
  • RCEL United States
  • BGX United States
  • Employees
  • RCEL N/A
  • BGX N/A
  • Industry
  • RCEL Medical/Dental Instruments
  • BGX Trusts Except Educational Religious and Charitable
  • Sector
  • RCEL Health Care
  • BGX Finance
  • Exchange
  • RCEL Nasdaq
  • BGX Nasdaq
  • Market Cap
  • RCEL 161.5M
  • BGX 150.8M
  • IPO Year
  • RCEL N/A
  • BGX N/A
  • Fundamental
  • Price
  • RCEL $5.19
  • BGX $12.19
  • Analyst Decision
  • RCEL Strong Buy
  • BGX
  • Analyst Count
  • RCEL 4
  • BGX 0
  • Target Price
  • RCEL $16.50
  • BGX N/A
  • AVG Volume (30 Days)
  • RCEL 287.8K
  • BGX 67.9K
  • Earning Date
  • RCEL 08-07-2025
  • BGX 01-01-0001
  • Dividend Yield
  • RCEL N/A
  • BGX 10.34%
  • EPS Growth
  • RCEL N/A
  • BGX N/A
  • EPS
  • RCEL N/A
  • BGX N/A
  • Revenue
  • RCEL $71,661,000.00
  • BGX N/A
  • Revenue This Year
  • RCEL $57.29
  • BGX N/A
  • Revenue Next Year
  • RCEL $28.07
  • BGX N/A
  • P/E Ratio
  • RCEL N/A
  • BGX N/A
  • Revenue Growth
  • RCEL 41.35
  • BGX N/A
  • 52 Week Low
  • RCEL $5.10
  • BGX $10.69
  • 52 Week High
  • RCEL $14.16
  • BGX $12.44
  • Technical
  • Relative Strength Index (RSI)
  • RCEL 29.07
  • BGX 50.93
  • Support Level
  • RCEL $5.10
  • BGX $12.14
  • Resistance Level
  • RCEL $6.33
  • BGX $12.26
  • Average True Range (ATR)
  • RCEL 0.32
  • BGX 0.09
  • MACD
  • RCEL 0.02
  • BGX -0.00
  • Stochastic Oscillator
  • RCEL 6.10
  • BGX 46.15

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

About BGX Blackstone Long Short Credit Income Fund

Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategy in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first- and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.

Share on Social Networks: